PRTA Stock Analysis: Buy, Sell, or Hold?
PRTA - Prothena Corporation plc Ordinary Shares
$9.25
-0.01 (-0.11%)
▼
5d:
+4.88%
30d:
+6.69%
90d:
-3.04%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When PRTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PRTA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: PRTA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: PRTA is currently trading at $9.25, which is considered fair relative to its 30-day fair value range of $8.79 to $9.54. From a valuation perspective, the stock is trading at a discount (Forward PE: -8.9) compared to its historical average (18.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PRTA is in a strong uptrend. Immediate support is located at $8.38, while resistance sits at $9.68.
Market Sentiment: PRTA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.00 (+126.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PRTA is in a strong uptrend. Immediate support is located at $8.38, while resistance sits at $9.68.
Market Sentiment: PRTA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.00 (+126.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$8.79 -
$9.54
Company Quality Score
60/100
(BUY)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
84.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 126.8% below Wall St target ($21.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Fair Price Analysis
30-Day Fair Range
$8.79 -
$9.54
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$0.92
(10.0%)
Support & Resistance Levels
Support Level
$8.38
Resistance Level
$9.68
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.90
Wall Street Target
$21.00
(+126.8%)
Revenue Growth (YoY)
-99.0%
PE vs Historical
-8.9 vs 18.0
CHEAP
Share & Embed Analysis
Last updated: March 30, 2026 4:49 PM ET
Data refreshes hourly during market hours. Next update: 5:49 PM
Data refreshes hourly during market hours. Next update: 5:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 48 HOLD |
